DS
NBIX icon

David Shaw’s Neurocrine Biosciences NBIX Stock Holding History

David Shaw’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$1.23M – 3913
2018
Q3 		$1.23M Hold
10,000
– – ﹤0.01% 2547
2018
Q2 		$982K Buy
+10,000
New +$895K ﹤0.01% 2715

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's NBIX Position: Q2 2026 in Review

David Shaw reduced its Neurocrine Biosciences (NBIX) stake by 94% in Q2 2026, selling an estimated $12.4M and leaving 5,599 shares worth $944K. The position accounts for ﹤0.01% of the portfolio, ranked #3786.

David Shaw first reported a position in NBIX in Q2 2013 and has held it in 46 quarters since. The position peaked at $30.9M in Q4 2022. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • David Shaw held 5,599 shares of Neurocrine Biosciences worth $944K as of Q2 2026.
  • David Shaw sold 83,585 Neurocrine Biosciences shares in Q2 2026, an estimated $12.4M.
  • Neurocrine Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3786 holding.
  • David Shaw first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 46 quarters since.
  • David Shaw's Neurocrine Biosciences position peaked at $30.9M in Q4 2022.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.